Regeneron周一表示，已与美国卫生机构延长协议，追加供应其埃博拉治疗药物，此前非洲疫情正在扩大。
Regeneron said on Monday it extended its agreement with a US health authority to provide additional supply of its Ebola treatment, amid a growing outbreak in Africa.
根据与美国生物医学高级研究与开发管理局（BARDA）达成的新协议，在2020年合同基础上扩大范围，Regeneron将供应其药物Inmazeb直至2031年，金额约为2.7亿美元。美国食品药品监督管理局（FDA）于2020年批准Inmazeb用于治疗由扎伊尔埃博拉病毒引起的感染。目前的埃博拉疫情由邦迪布焦毒株引起，目前尚无获批的针对性抗病毒治疗药物或获许可的疫苗。Regeneron表示，正在测试其实验性疗法maftivimab，作为治疗邦迪布焦病毒的潜在药物。
Here are some details:
该疫情于5月首次在刚果民主共和国报告，现已蔓延至东非、中非和西非的四个国家——这是迄今为止非洲大陆任何埃博拉疫情中地理传播范围最广的一次。目前的疫情已在刚果（金）感染近1万人，造成4800多人死亡。该疾病可引起发热、呕吐、腹泻，严重时出现内出血和外出血。
The new agreement with the US Biomedical Advanced Research and Development Authority, expanding a 2020 contract, will see Regeneron supply doses of its drug Inmazeb through 2031 for about $270 million The US Food and Drug Administration approved Inmazeb in 2020 for the treatment of infection caused by Zaire ebolavirus The current Ebola outbreak is caused by the Bundibugyo strain, for which there is no approved specific antiviral treatment or licensed vaccine Regeneron said it is testing its experimental therapy, maftivimab, as a potential treatment for the Bundibugyo virus The outbreak, first reported in the Democratic Republic of Congo in May, has now spread to four countries across East, Central and West Africa — the widest geographic spread of any Ebola outbreak on the continent to date The current outbreak has infected nearly 10,000 people and killed more than 4,800 in Congo The disease can cause fever, vomiting, diarrhea and, in severe cases, internal and external bleeding